Exosome Component 9 Antibody (1090209) [Unconjugated]

Exosome Component 9 was detected in immersion fixed paraffin-embedded sections of human colon cancer using Mouse Anti-Human Exosome Component 9 Monoclonal Antibody (Catalog # MAB11616) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the nucleus. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Exosome Component 9 was detected in immersion fixed U251‑MG human malignant glioblastoma cell line using Mouse Anti-Human Exosome Component 9 Monoclonal Antibody (Catalog # MAB11616) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the nucleus. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

• Reactivity: Hu
• Applications: IHC, ICC/IF
• Clone: 1090209
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

Exosome Component 9 Antibody (1090209) [Unconjugated] Summary

• Immunogen: Synthetic Peptide
  Accession # Q06265
• Specificity: Detects a synthetic peptide specific for hEXOSC9 around amino acid 300 in Direct ELISA.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry 3-25 ug/mL
  • Immunohistochemistry 3-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Exosome Component 9 Antibody (1090209) [Unconjugated]

• Autoantigen PM/Scl 1
• EC 3.1.13
• exosome complex component RRP45
• exosome complex exonuclease RRP45
• Exosome Component 9
• p5
• p6
• P75 polymyositis-scleroderma overlap syndrome associated autoantigen
• PCH1D
• PM/Scl-75
• PMSCL autoantigen, 75kD
• PMSCL1
• polymyositis/scleroderma autoantigen 1 (75kD)
• Polymyositis/scleroderma autoantigen 1
• polymyositis/scleroderma autoantigen 1, 75kDa
• RRP45
• Rrp45p

Background

Exosome Component 9 (EXOSC9) is a 49 kDa protein and one of the six core proteins of the RNA exosome complex. It is known that EXOSC9 is necessary for the normal differentiation of epidermal tissues. EXOSC9 is also necessary for P-body formation, stress resistance and tumorigenicity in cancers. Depletion of EXOSC9 attenuates stress resistance and P-body formation in cancer cells and higher EXOSC9 activity correlates with poor prognosis in some types of cancers.

1. Yoshino S, Matsui Y, Fukui Y, Seki M, Yamaguchi K, Kanamori A, Saitoh Y, Shimamura T, Suzuki Y, Furukawa Y, Kaneko S, Seiki M, Murakami Y, Inoue JI, Sakamoto T. EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells. Sci Rep. 2020 Jun 9;10(1):9275. doi: 10.1038/s41598-020-66455-2. PMID: 32518284; PMCID: PMC7283315. 
2. Quttina M, Waiters KD, Khan AF, Karami S, Peidl AS, Babajide MF, Pennington J, Merchant FA, Bawa-Khalfe T. Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer. Cells. 2023 Oct 20;12(20):2495. doi: 10.3390/cells12202495. PMID: 37887339; PMCID: PMC10605189.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q06265(Human)